Another Amylin investor group rebels

Now, Amylin Pharmaceuticals faces two dissident investor groups: Eastbourne Capital Management has joined Carl Icahn's group in backing a slate of director candidates, saying it has "lost confidence" in the San Diego company's management. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.